annb0t
Top 20
SYDNEY, June 13, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data regarding the activity of paxalisib in two forms of childhood brain cancer with poor prognosis and limited treatment options.
The data is the subject of two poster presentations at the 20th International Symposium on Pediatric Neuro-Oncology (ISPNO), held in Hamburg, Germany, from 12-15 June 2022.
The first ...
>>> Read more: POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING
The data is the subject of two poster presentations at the 20th International Symposium on Pediatric Neuro-Oncology (ISPNO), held in Hamburg, Germany, from 12-15 June 2022.
The first ...
>>> Read more: POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING
